Gilead Sciences' Biktarvy Gets Expansion Approval From FDA for People With Suppressed Viral Loads

 Gilead Sciences' HIV treatment Biktarvy was expanded to treat people with suppressed viral loads.

The biopharmaceutical company said the expansion, approved by the Food and Drug Administration, is for treatment of people with HIV who have suppressed viral loads with known or suspected M184V/I resistance, a common form of treatment resistance.

Gilead said HIV treatment resistance is permanent and irreversible, which can jeopardize future treatment options for people with HIV.

https://www.marketscreener.com/quote/stock/GILEAD-SCIENCES-INC-4876/news/Gilead-Sciences-Biktarvy-Gets-Expansion-Approval-From-FDA-for-People-With-Suppressed-Viral-Loads-46032435/